Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARCINOSIS trial of neoadjuvant FOLFOXIRI + bevacizumab for peritoneal metastases from colorectal cancer
2015-002917-30Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Jul 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, irinotecan, oxaliplatin and bevacizumab in colorectal cancer (CRC), sponsored by Medical University of Vienna. Primary endpoint: Histopathological response. Started Jul 2015; status: terminated.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatinbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2015-002917-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002917-30.